Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


LMTX , A new era of Alzheimer's treatment

No description

shrouk elbadry

on 12 November 2016

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of LMTX , A new era of Alzheimer's treatment

LMTX , A new era of Alzheimer's treatment
Faculty of pharmacy Mansoura university.
By :-

1-Sally Reda El.Salamouny.
2-Basma Hassan El.asklany.
3-Micheal Magdi Fares.
4-Shrouk Mahmoud El.badry.
Under supervision of:-
Dr: Mohamed Ahmed Saleh.
LMTX , A new era of Alzheimer's treatment
Alzheimer's disease:-

Is a slowly progressing neurodegenerative disease. In which, abnormal deposits of a protein called amyloid-beta forms sticky plaques in the brain, and strands of the protein tau twist around causing :dementia, loss of memory, thinking,
and many skills.
Aim of drug development.

Clinical benefits of the available pharmacological treatment for AD with anti dementia drugs are to target symptoms,and improve quality of life .

So development of new pharmaceutical compounds with
disease-modifying properties
became a need.
Anti-amyloid therapy
Tau-oriented strategies
pharmaceutical compounds with disease-modifying properties
, is the first one with its mode of action, it works by undoing the existing tangles that cause dementia, thereby slowing and even arresting memory loss, and preventing formation of new ones through proteasomal and macroautophagic degradation of the protein

from MTC to LMTX .
Phase- 2
after 1 and 2 years of treatment with
Methylene blue induces autophagy which is a lysosomal degradative process in three steps :
1) Induction .
2) Elongation .
3) Vacuole formation .
The drug did seem to work for the subset of patients — about 15 percent of those in the study —
who took LMTX as their only therapy.

The other 85 percent of patients took an existing Alzheimer’s drug in addition to either LMTX or a placebo
Tau aggregation is one of the most important causes of Neurodegeneration .

Methylthioninium chloride ( MTC ) is thought to be a tau aggregation inhibitor .
Many researches have been done for reassuring LMTX as a second generation of MTC effectiveness.

It had been declared by phase three , that LMTX is not highly effective for treatment of Alzheimer’s .

However , We are still hoping that LMTX will be the reason for a new era of Alzheimer’s treatment , or at least its applied researches will be an effective step for the hoped drug for overcoming this exhausting disease.
Summery :-
Alzheimer's disease is a slowly progressive neurodegenrative disease
Amyloid plaques and tau tangles formation or aggregation are thought to contribute to the degradation of the nerve cells in the brain and the subsequent symptoms of Alzheimer’s disease.

Methylthioninium Chloride ( MTC) is thought to be a tau aggregation inhibitor by induction of autophagy of tau tangles.

Rember®, is the 1st generation of tau aggregation inhbitors.
LMTX® (leuco-methylthioninium) , is the 2nd generation and it has more bioavailability and tolerability

LMTX® has been the subject of the recent Phase 3 trials, and it is a hopeful treatment for Alzheimer’s.
Sub-phase 1
MTC was able to reverse the behavioural and pathological effects arising from tau pathology in animal models and the team concluded that MTC had the potential to slow the rate of Alzheimer’s progression, and potentially restore neuronal function, particularly at early stages of the disease.

It showed that there are limitations in the absorption of the active component of rember®, methylthioninium (MT), when it was given in the charged MT+ form. MT+ must be converted to the uncharged leuco-MT form (LMT) by a thiazine reductase enzyme .

Full transcript